BioCryst Pharmaceuticals (BCRX) receives a letter from FDA which it says "outlines a pathway by...

|About: BioCryst Pharmaceuticals, Inc. (BCRX)|By:, SA News Editor

BioCryst Pharmaceuticals (BCRX) receives a letter from FDA which it says "outlines a pathway by which an NDA [could be filed] seeking regulatory approval of intravenous permavir." Last November, shares were nearly cut in half after permavir disappointed in clinical trials. Shares +15% premarket.